Prostaglandins as PPAR γ modulators in adipogenesis

PPAR Research

Volumn , Issue , 2012, Pages

  Fujimori, Ko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ADIPOCYTE; ADIPOGENESIS; CELL DIFFERENTIATION; ENZYME ACTIVITY; NONHUMAN; POSITIVE FEEDBACK; PROSTAGLANDIN SYNTHESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; WHITE ADIPOSE TISSUE;

EID: 84872815504     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/527607     Document Type: Review

References (75)

1. Friedman J. M., Modern science versus the stigma of obesity. Nature Medicine 2004 10 6 563 569 2-s2.0-2942716780 10.1038/nm0604-563 (Pubitemid 38796839)
2. Attie A. D., Scherer P. E., Adipocyte metabolism and obesity. Journal of Lipid Research 2009 50 S395 S399 2-s2.0-66349115342 10.1194/jlr.R800057-JLR200
3. Cornier M. A., Dabelea D., Hernandez T. L., Lindstrom R. C., Steig A. J., Stob N. R., Van Pelt R. E., Wang H., Eckel R. H., The metabolic syndrome. Endocrine Reviews 2008 29 7 777 822 2-s2.0-57349096045 10.1210/er.2008-0024
4. Pi-Sunyer X., The medical risks of obesity. Postgraduate Medicine 2009 121 6 21 33 2-s2.0-73949153085 10.3810/pgm.2009.11.2074
5. Galic S., Oakhill J. S., Steinberg G. R., Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology 2010 316 2 129 139 2-s2.0-72449191699 10.1016/j.mce.2009.08.018
6. Rasouli N., Kern P. A., Adipocytokines and the metabolic complications of obesity. Journal of Clinical Endocrinology and Metabolism 2008 93 11 s64 s73 2-s2.0-55849114349 10.1210/jc.2008-1613
7. Antuna-Puente B., Feve B., Fellahi S., Bastard J. P., Adipokines: the missing link between insulin resistance and obesity. Diabetes and Metabolism 2008 34 1 2 11 2-s2.0-39149143637 10.1016/j.diabet.2007.09.004
8. Matsuzawa Y., Adiponectin: a key player in obesity related disorders. Current Pharmaceutical Design 2010 16 17 1896 1901 2-s2.0-77953508725 10.2174/138161210791208893
9. Lefterova M. I., Lazar M. A., New developments in adipogenesis. Trends in Endocrinology and Metabolism 2009 20 3 107 114 2-s2.0-62949236601 10.1016/j.tem.2008.11.005
10. Rosen E., Eguchi J., Xu Z., Transcriptional targets in adipocyte biology. Expert Opinion on Therapeutic Targets 2009 13 8 975 986 2-s2.0-69149095335 10.1517/14728220903039706
11. Anghel S. I., Wahli W., Fat poetry: a kingdom for PPAR γ Cell Research 2007 17 6 486 511 2-s2.0-34250803903 10.1038/cr.2007.48 (Pubitemid 46980946)
12. Christodoulides C., Vidal-Puig A., PPARs and adipocyte function. Molecular and Cellular Endocrinology 2010 318 1-2 61 68 2-s2.0-77049090816 10.1016/j.mce.2009.09.014
13. White U. A., Stephens J. M., Transcriptional factors that promote formation of white adipose tissue. Molecular and Cellular Endocrinology 2010 318 1-2 10 14 2-s2.0-76749146390 10.1016/j.mce.2009.08.023
14. Siersbæk R., Nielsen R., Mandrup S., PPAR γ in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Letters 2010 584 15 3242 3249 2-s2.0-77955274518 10.1016/j.febslet.2010.06.010
15. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPAR γ Annual Review of Biochemistry 2008 77 289 312 2-s2.0-50649097541 10.1146/annurev.biochem.77.061307.091829
16. Sharma A. M., Staels B., Review: peroxisome proliferator-activated receptor γ and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology and Metabolism 2007 92 2 386 395 2-s2.0-33847006604 10.1210/jc.2006-1268
17. Tabe Y., Konopleva M., Andreeff M., Ohsaka A., Effects of PPAR γ ligands on leukemia. PPAR Research 2012 2012 8 10.1155/2012/483656 483656
18. Cariou B., Charbonnel B., Staels B., Thiazolidinediones and PPAR γ agonists: time for a reassessment. Trends in Endocrinology and Metabolism 2012 23 5 205 215
19. Penumetcha M., Santanam N., Nutraceuticals as ligands of PPAR γ PPAR Research 2012 2012 7 10.1155/2012/858352 858352
20. 2 is a ligand for the adipocyte determination factor PPAR γ Cell 1995 83 5 803 812 2-s2.0-0028972025 (Pubitemid 3006324)
21. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995 83 5 813 819 2-s2.0-0028972026 (Pubitemid 3006325)
22. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323 2-s2.0-0006132932 10.1073/pnas.94.9.4318 (Pubitemid 27194239)
23. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M. G., Wahli W., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molecular Endocrinology 1997 11 6 779 791 2-s2.0-0030985318 10.1210/me.11.6.779 (Pubitemid 27225305)
24. Kobayashi T., Fujimori K., Very long chain-fatty acids enhance adipogenesis through co-regulation of Elovl3 and PPAR γ in 3T3-L1 cells. American Journal of Physiology, Endocrinology and Metabolism 2012 302 12 E1461 E1471
25. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ Cell 1998 93 2 229 240 2-s2.0-0032540325 10.1016/S0092-8674(00)81574-3 (Pubitemid 28180856)
26. Tontonoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M., PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 93 2 241 252 2-s2.0-0032540012 10.1016/S0092-8674(00)81575-5 (Pubitemid 28180857)
27. Peraza M. A., Burdick A. D., Marin H. E., Gonzalez F. J., Peters J. M., The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicological Sciences 2006 90 2 269 295 2-s2.0-33645112691 10.1093/toxsci/kfj062
28. 2 research: from cells to animals to humans. Progress in Lipid Research 2011 50 2 152 192 2-s2.0-79952080909 10.1016/j.plipres.2010.12.001
29. Smith W. L., Urade Y., Jakobsson P. J., Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chemical Reviews 2011 111 10 5821 5865
30. Narumiya S., Furuyashiki T., Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. FASEB Journal 2011 25 3 813 818 2-s2.0-79954588651 10.1096/fj.11-0302ufm
31. Fujimori K., Ueno T., Nagata N., Kashiwagi K., Aritake K., Amano F., Urade Y., Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2α synthase. Journal of Biological Chemistry 2010 285 12 8880 8886 2-s2.0-77950575505 10.1074/jbc.M109.077164
32. Yan H., Kermouni A., Abdel-Hafez M., Lau D. C. W., Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells. Journal of Lipid Research 2003 44 2 424 429 2-s2.0-0141588939 10.1194/jlr.M200357-JLR200 (Pubitemid 37287786)
33. Chu X., Nishimura K., Jisaka M., Nagaya T., Shono F., Yokota K., Up-regulation of adipogenesis in adipocytes expressing stably cyclooxygenase-2 in the antisense direction. Prostaglandins and Other Lipid Mediators 2010 91 1-2 1 9 2-s2.0-74849132740 10.1016/j.prostaglandins.2009.10.002
34. Fajas L., Miard S., Briggs M. R., Auwerx J., Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase. Journal of Lipid Research 2003 44 9 1652 1659 2-s2.0-0141571073 10.1194/jlr.M300248-JLR200 (Pubitemid 37185875)
35. Vegiopoulos A., Müller-Decker K., Strzoda D., Schmitt I., Chichelnitskiy E., Ostertag A., Diaz M. B., Rozman J., De Angelis M. H., Nüsing R. M., Meyer C. W., Wahli W., Klingenspor M., Herzig S., Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 2010 328 5982 1158 1161 2-s2.0-77952970098 10.1126/science.1186034
36. Ghoshal S., Trivedi D. B., Graf G. A., Loftin C. D., Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. Journal of Biological Chemistry 2011 286 1 889 898 2-s2.0-78650953860 10.1074/jbc.M110.139139
37. Casimir D. A., Miller C. W., Ntambi J. M., Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation 1996 60 4 203 210 2-s2.0-0029791565 10.1007/ s002580050150 (Pubitemid 26265757)
38. Liu L., Clipstone N. A., Prostaglandin F2α inhibits adipocyte differentiation via a G α q-calcium-calcineurin-dependent signaling pathway. Journal of Cellular Biochemistry 2007 100 1 161 173 2-s2.0-33845609092 10.1002/jcb.21044 (Pubitemid 44958187)
39. Miller C. W., Casimir D. A., Ntambi J. M., The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2α Endocrinology 1996 137 12 5641 5650 2-s2.0-0030444564
40. Serrero G., Lepak N. M., Prostaglandin F2α receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochemical and Biophysical Research Communications 1997 233 1 200 202 2-s2.0-0031557409 10.1006/bbrc.1997.6433 (Pubitemid 27215935)
41. Reginato M. J., Krakow S. L., Bailey S. T., Lazar M. A., Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ Journal of Biological Chemistry 1998 273 4 1855 1858 2-s2.0-0031939716 10.1074/jbc.273.4.1855 (Pubitemid 28069225)
42. Tsuboi H., Sugimoto Y., Kainoh T., Ichikawa A., Prostanoid EP4 receptor is involved in suppression of 3T3-L1 adipocyte differentiation. Biochemical and Biophysical Research Communications 2004 322 3 1066 1072 2-s2.0-4444373075 10.1016/j.bbrc.2004.08.018 (Pubitemid 39164462)
43. 2-EP4 signaling suppresses adipocyte differentiation in mouse embryonic fibroblasts via an autocrine mechanism. Journal of Lipid Research 2011 52 8 1500 1508 2-s2.0-79960673188 10.1194/jlr.M013615
44. 2 Journal of Biochemistry 2011 150 6 593 596
45. Kabututu Z., Manin M., Pointud J. C., Maruyama T., Nagata N., Lambert S., Lefrançois-Martinez A. M., Martinez A., Urade Y., Prostaglandin F2α synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. Journal of Biochemistry 2009 145 2 161 168 2-s2.0-59449086542 10.1093/jb/mvn152
46. Tirard J., Gout J., Lefrançois-Martinez A. M., Martinez A., Begeot M., Naville D., A novel inhibitory protein in adipose tissue, the aldo-keto reductase AKR1B7: its role in adipogenesis. Endocrinology 2007 148 5 1996 2005 2-s2.0-34249777561 10.1210/en.2006-1707 (Pubitemid 46997035)
47. Moriuchi H., Koda N., Okuda-Ashitaka E., Daiyasu H., Ogasawara K., Toh H., Ito S., Woodward D. F., Watanabe K., Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily. Journal of Biological Chemistry 2008 283 2 792 801 2-s2.0-38149045106 10.1074/jbc.M705638200
48. Byrns M. C., Jin Y., Penning T. M., Inhibitors of type 5 17 β -hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. Journal of Steroid Biochemistry and Molecular Biology 2011 125 1-2 95 104 2-s2.0-79957722662 10.1016/j.jsbmb.2010.11.004
49. Volat F. E., Pointud J. C., Pastel E., Morio B., Sion B., Hamard G., Guichardant M., Colas R., Lefrancois-Martinez A. M., Martinez;():- A., Depressed levels of prostaglandin F2α in mice lacking akr1b7 increase basal adiposity and predispose to diet-Induced obesity. Diabetes 2012 61 11 2796 2806
50. Ueno T., Fujimori K., Novel suppression mechanism operating in early phase of adipogenesis by positive feedback loop for enhancement of cyclooxygenase-2 expression through prostaglandin F2α receptor mediated activation of MEK/ERK-CREB cascade. FEBS Journal 2011 278 16 2901 2912 2-s2.0-79961023886 10.1111/j.1742-4658.2011.08213.x
51. 2 suppression of 3T3-L1 adipocyte differentiation. Biochemical and Biophysical Research Communications 2004 322 3 911 917 2-s2.0-4444232615 10.1016/j.bbrc.2004.07.194 (Pubitemid 39164439)
52. Xie Y., Kang X., Ackerman W. E., Belury M. A., Koster C., Rovin B. H., Landon M. B., Kniss D. A., Differentiation-dependent regulation of the cyclooxygenase cascade during adipogenesis suggests a complex role for prostaglandins. Diabetes, Obesity and Metabolism 2006 8 1 83 93 2-s2.0-33646008282 10.1111/j.1463-1326.2005.00472.x
53. 2 synthase-1 in adipose tissue by high-fat feeding. Obesity 2007 15 1 60 68 2-s2.0-33846876327 10.1038/oby.2007.514 (Pubitemid 46219784)
54. Hara S., Kamei D., Sasaki Y., Tanemoto A., Nakatani Y., Murakami M., Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie 2010 92 6 651 659 2-s2.0-77953293751 10.1016/j.biochi.2010.02.007
55. 2 at new glance: novel insights in functional diversity offer therapeutic chances. International Journal of Biochemistry and Cell Biology 2010 42 2 198 201 2-s2.0-73749088151 10.1016/j.biocel.2009.09.015
56. Jakobsson P. J., Thorén S., Morgenstern R., Samuelsson B., Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7220 7225 2-s2.0-0033594963 10.1073/pnas.96.13.7220 (Pubitemid 29299642)
57. Samuelsson B., Morgenstern R., Jakobsson P. J., Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacological Reviews 2007 59 3 207 224 2-s2.0-34748817976 10.1124/pr.59.3.1 (Pubitemid 47481434)
58. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., Ito S., Watanabe K., Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochemical and Biophysical Research Communications 2002 291 4 884 889 2-s2.0-0036291419 10.1006/bbrc.2002.6531 (Pubitemid 34694357)
59. 2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. Journal of Biological Chemistry 2000 275 42 32775 32782 2-s2.0-0034693050
60. 2 acting through PPAR γ -dependent and independent pathways. Gene 2012 505 1 46 52
61. 2 and aldo-keto reductase 1B3-produced PG F2α PloS ONE 2012 7 9 e44698
62. Urade Y., Hayaishi O., Prostaglandin D synthase: structure and function. Vitamins and Hormones 2000 58 89 120 2-s2.0-0033627825
63. Urade Y., Hayaishi O., Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochimica et Biophysica Acta 2000 1482 1-2 259 271 2-s2.0-0034684216 10.1016/S0167-4838(00)00161-8
64. Kanaoka Y., Urade Y., Hematopoietic prostaglandin D synthase. Prostaglandins Leukotrienes and Essential Fatty Acids 2003 69 2-3 163 167 2-s2.0-0042122480 10.1016/S0952-3278(03)00077-2 (Pubitemid 36976171)
65. 2 and the ligation of PPAR γ Journal of Clinical Investigation 2003 112 6 945 955 2-s2.0-0142186679 10.1172/JCI200318012 (Pubitemid 38063752)
66. 2 and its application to the measurement of the endogenous product generated by cultured adipocytes during the maturation phase. Prostaglandins and Other Lipid Mediators 2011 94 3-4 73 80 2-s2.0-79954415720 10.1016/j.prostaglandins.2010.12.005
67. Fujimori K., Aritake K., Urade Y., A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c. Journal of Biological Chemistry 2007 282 25 18458 18466 2-s2.0-34547123829 10.1074/jbc.M701141200 (Pubitemid 47100233)
68. 2 synthase knock-out mice. Journal of Biological Chemistry 2005 280 33 29946 29955 2-s2.0-23844540300 10.1074/jbc.M502927200 (Pubitemid 41177073)
69. 2 synthase stimulates glucose transport via enhanced GLUT4 translocation. Prostaglandins and Other Lipid Mediators 2008 87 1-4 34 41 2-s2.0-55549121198 10.1016/j.prostaglandins.2008.06.001
70. Tanaka R., Miwa Y., Mou K., Tomikawa M., Eguchi N., Urade Y., Takahashi-Yanaga F., Morimoto S., Wake N., Sasaguri T., Knockout of the l-pgds gene aggravates obesity and atherosclerosis in mice. Biochemical and Biophysical Research Communications 2009 378 4 851 856 2-s2.0-57849159302 10.1016/j.bbrc.2008.11.152
71. 2 in vivo. FEBS Journal 2010 277 6 1410 1419 2-s2.0-77749316918 10.1111/j.1742-4658.2010.07565.x
72. 2+-elevating agent. Journal of Biological Chemistry 1992 267 16 11092 11097 2-s2.0-0026702181
73. 2: physiological implications. Endocrinology 1992 131 5 2393 2398 2-s2.0-0026470624 10.1210/en.131.5.2393
74. Aubert J., Saint-Marc P., Belmonte N., Dani C., Négrel R., Ailhaud G., Prostacyclin IP receptor up-regulates the early expression of C/EBP β and C/EBP δ in preadipose cells. Molecular and Cellular Endocrinology 2000 160 1-2 149 156 2-s2.0-0034712348 10.1016/S0303-7207(99)00210-5 (Pubitemid 30129061)
75. Massiera F., Saint-Marc P., Seydoux J., Murata T., Kobayashi T., Narumiya S., Guesnet P., Amri E. Z., Negrel R., Ailhaud G., Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? Journal of Lipid Research 2003 44 2 271 279 2-s2.0-10744233743 10.1194/jlr.M200346-JLR200 (Pubitemid 37287770)